Exosome Diagnostics and Therapeutics Market Size, Share, and Industry Analysis, By Product Type (Exosome Diagnostics and Exosome Therapeutics), By Application (Oncology, Neurology, Cardiometabolic, Inflammation, Regenerative Medicine, and Others), By End User (Hospitals & Diagnostic Labs, Pharma & Biotechnology Companies, Academic & Research Institutes, CROs & CDMOs, and Others), and Regional Forecast till 2034

The exosome diagnostics and therapeutics market size was valued at USD 0.60 billion in 2025. The market is projected to grow from USD 0.72 billion in 2026 to USD 3.00 billion by 2034, exhibiting a CAGR of 19.6% during the forecast period.

The exosome diagnostics and therapeutics market is witnessing notable growth due to a growing focus on molecular biology and precision medicine, as well as increasing research and development efforts to explore exosome-based biomarkers, which are expected to boost demand for exosome therapeutics and diagnostics.

Underscoring the high demand, many key companies are engaging in strategic activities, such as mergers and acquisitions, to capitalize on the market's growth potential.

• For instance, in June 2025, Bio-Techne Corporation acquired Exosome Diagnostics Inc.'s business, including the ExoDx Prostate (EPI) test, a CLIA-certified clinical laboratory, and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar.

Furthermore, strategic collaborations, news product launches, and key acquisitions helped diversify the product offerings of key companies and strengthen their market position.

Exosome Diagnostics and Therapeutics Market Driver

Rising Demand for Non-Invasive Diagnostics to Drive Market Growth

Rising demand for non-invasive diagnostics is driving the exosome market. Healthcare systems are striving to detect and monitor diseases with a reduced patient burden and lower clinical risk. Compared to a tissue biopsy, a urine- or blood-based test is easier to collect, can be repeated over time, and reduces the chance of procedure-related complications. This improves patient acceptance and supports earlier risk assessment and ongoing monitoring, making physicians and laboratories more willing to adopt validated liquid-biopsy tools. As adoption grows, companies invest more in exosome isolation, biomarker panels, and clinical validation.

• For instance, in September 2024, PreAnalytiX GmbH, in collaboration with QIAGEN N.V. and BD, launched the PAXgene Urine Liquid Biopsy Set, which enabled the reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR, and next-generation sequencing (NGS)—such developments are driving market growth.

Download Free sample to learn more about this report.

Underscoring the importance of exosomes, the research and development in the field is increasing. According to the report published by the NIH in May 2022, titled ‘Exosomes in the Field of Neuroscience: A Scientometric Study and Visualization Analysis’, 162 publications were introduced in 2021 in therapeutic applications of exosomes in neuroscience alone.

Exosome Diagnostics and Therapeutics Market Restraint

Regulatory and Compliance Burden Hampering Market Growth

One of the major factors restraining the market growth is the regulatory and compliance burden. Exosome products must meet strict regulatory requirements for safety, identity, purity, and manufacturing controls, resulting in stringent regulations. Companies must invest heavily in regulatory planning, validated processes, and controlled clinical pathways. Fail.

• For example, in August 20205, Platinum Biologics LLC received an FDA Warning Letter as it was found selling two exosome products, NanoEx and Nano Xsomes, along with umbilical cord–derived products for allogeneic use, and the FDA determined these were unapproved new drugs and unlicensed biological products being marketed with disease/condition treatment claims. Such factors hamper market growth.

Exosome Diagnostics and Therapeutics Market Opportunity

Expansion into Regenerative Medicine Indications for Therapeutic Application Offers Lucrative Market Growth Opportunity

Expansion into regenerative medicine indications is a strong growth opportunity for exosome therapeutics markets. Conditions such as wound closure, pain/function improvement, tissue repair often have large patient pools, clear unmet needs, creating robust demand. Exosome-based therapies can help modulate inflammation and support healing, which is especially relevant in chronic wounds and degenerative disorders, where conventional care is often slow, costly, and sometimes ineffective.

 Underscoring these advantages, many clinical-stage pharmaceutical companies are focusing on expanding their pipeline candidates and streamlining their focus toward research and development.

• For instance, in January 2025, RION completed patient enrollment in its Phase 2 clinical trial for Purified Exosome Product (PEP) in the treatment of diabetic foot ulcers (DFUs). This milestone marks a significant step forward in the company’s mission to develop cutting-edge therapies addressing chronic wound care.

Segmentation

Key Insights

The report covers the following key insights:

• Key Industry Developments
• Overview: Advancements in Exosome Diagnostics and Therapeutics
• New Product Launches, By Key Players
• Analysis: Emerging Application Areas for Exosome Diagnostics and Therapeutics
• Pipeline Analysis, By Key Players

Analysis by Product Type

Based on product type, the global exosome diagnostics and therapeutics market is segmented into exosome diagnostics and exosome therapeutics.

Among these, exosome diagnostics is expected to dominate the market. The diagnostics segment has near-term, revenue-generating clinical use cases, unlike therapeutics that are still in early clinical development. In diagnostics, exosomes are utilized as a non-invasive liquid biopsy, supporting faster adoption by clinicians and laboratories. Underscoring these factors, many key companies are focusing on enhancing their exosome diagnostic offerings and driving segmental growth.

• For instance, in February 2023, Biological Dynamics, Inc. completed the analytical and clinical validation of its lab-developed test (LDT), ExoVita Pancreas, in the company’s CLIA-certified and CAP-accredited laboratory.

Analysis by Application

By application, the market is divided into oncology, neurology, cardiometabolic, inflammation, regenerative medicine, and others.

Oncology dominated the market due to strong demand for cancer care, including early detection and treatment monitoring. Exosomes are well-suited to these needs as they carry tumor-related RNA/protein signals in accessible biofluids. As a result, the majority of clinical applications of exosome-based liquid biopsy are focused on cancer and heavily oriented toward translating exosome biomarker workflows into routine oncology decision support. Due to these advantages, many key companies are investing profoundly to develop pipeline candidates and drive growth in the segment.

• For instance, in November 2021, Codiak BioSciences, Inc., a company focused on exosome-based therapeutics as a new class of medicines, received a new drug application from the U.S. FDA for exoASO-STAT6. exoASO-STAT6 is Codiak’s third engineered exosome therapeutic candidate to be cleared for clinical evaluation.

Analysis by End User

In terms of end-user, the market is divided into hospitals & diagnostic labs, pharma & biotechnology companies, academic & research institutes, CROs & CDMOs, and others.

The pharma and biotechnology companies segment is expected to hold a leading share in the global market. The segment accounted for the largest share as it is the primary consumer of exosomes for the production of therapeutic offerings. They fund and run therapeutic pipeline development, utilizing exosome biomarkers in drug discovery and translational research. Their programs drive downstream demand for CROs/CDMOs for analytical testing, process development, and manufacturing. Due to these factors, the segment is anticipated to dominate the market.

• For instance, in January 2023, Sartorius AG collaborated with RoosterBio to advance downstream purification processes for the manufacture of exosomes. Such developments are expected to drive the segmental growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 40% of the global exosome diagnostics and therapeutics market in 2025. The region's high market share is attributed to a strong ecosystem for precision diagnostics, faster clinical adoption, and rising investment in pipeline development.

The region is witnessing strategic collaborations among key players to bring forward innovative therapeutic offerings and capitalize on market growth.

• For instance, in April 2025, RoosterBio, Inc., collaborated with Thermo Fisher Scientific to accelerate the availability of new cell and exosome therapies that have the potential to revolutionize the treatment of degenerative diseases.

Europe is expected to grow at a significant CAGR during the forecast period. The growth in Europe is supported by public funding and industrialization programs that help companies transition from research to the production of exosome therapeutics. The region is focusing on strengthening its biomanufacturing capacity and scaling bioproduction.

The region also experiences robust collaboration among academic research and translational partnerships, which drive pipeline development and support market growth in the region.

• For instance, in October 2025, EVerZom, a French biotechnology company specializing in exosome-based therapies for regenerative medicine applications, secured an investment of USD 10.8 million. This capital enabled the company to launch its first clinical trial of EVerGel, expanding the therapeutic potential of its exosomes into new indications.

Asia Pacific is expected to grow at a stable CAGR during the forecast period.  The strong growth in the region is attributed to increasing investment in biomanufacturing capacity, growing CDMO/CRDMO capabilities, and strategic partnerships in the region to scale production of advanced therapies efficiently.

• For instance, in January 2026, Pandorum Technologies collaborated with Hyderabad-based Nucelion Therapeutics to expand the company's manufacturing capabilities for its exosome-based therapeutic platform across the Asia Pacific region. Such developments are driving the region's growth.

Key Players covered

The global exosome diagnostics and therapeutics market is semi-consolidated, with a few players capturing a significant market share. The report includes the profiles of the following key players.

• Thermo Fisher Scientific Inc. (U.S.)
• QIAGEN (Germany)
• Bio-Techne (U.S.)
• System Biosciences, LLC.  (U.S.)
• Miltenyi Biotec (Germany)
• Sartorius AG (Germany)
• Spectris (U.K.)
• Particle Metrix GmbH (Germany)
• Mdxhealth (Belgium)
• Exopharm (Australia)

Key Industry Developments

• January 2026: Esco Aster announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. Shine-On Biomedical sponsored high-yield exosome development using Esco Aster's cell line platform.
• November 2022: Sartorius BIA Separations (BIA), a subsidiary of Sartorius AG, collaborated with Exopharm, a company specializing in medicines utilizing exosomes, or extracellular vesicles, and announced. The collaboration aimed to utilize Exopharm’s patented LEAP technology in conjunction with BIA’s Convective Interaction Media chromatography for enhanced large-scale production and commercialization of therapeutic exosomes.